Adults 18 to 95, any sex, with Understand the Effects of tACS on the Brain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Resting Motor ThresholdPrimary· Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS
The peak-to-peak amplitude of the muscle signal from the resting motor threshold.
Before
Group
Value
95% CI
Resting Motor Threshold With tACS
76.5
± 26.6
After
Group
Value
95% CI
Resting Motor Threshold With tACS
108.7
± 43.2
30 min After
Group
Value
95% CI
Resting Motor Threshold With tACS
130.1
± 45
1 hour After
Group
Value
95% CI
Resting Motor Threshold With tACS
85.8
± 25.1
Active Motor ThresholdSecondary· Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS
Cortical silent period measured post-MEP.
Before
Group
Value
95% CI
Active Motor Threshold With tACS
131.1
After
Group
Value
95% CI
Active Motor Threshold With tACS
123.1
30 min After
Group
Value
95% CI
Active Motor Threshold With tACS
81.4
1 hour After
Group
Value
95% CI
Active Motor Threshold With tACS
108.75
Sponsor's own description
Previous studies have looked at the potential of using transcranial direct current stimulation (tDCS) to prime the brain in order to lower the resting motor threshold. The resting motor threshold (RMT) is the intensity at which repeated transcranial magnetic stimulation (rTMS) is applied for treatments. The RMT is the lowest intensity at which the participant's muscle responds with the motor evoked potential peak-to-peak amplitude greater than 50μV for 5 of 10 trials when the hand is relaxed. The active motor threshold (AMT) is the lowest intensity that produces MEP with peak-to-peak amplitude greater than 100 μV for 5 of 10 trials while the participant maintains 10-30% of maximal voluntary contraction. The RMT and AMT is different for each person and the high intensity TMS pulses can be difficult for some of the patients in the current Alzheimer's rTMS treatment study to tolerate. Therefore, if the treatment can still be applied with lower intensities, it would be more tolerable for some people. The limited research on both tDCS and transcranial alternating current stimulation (tACS) in priming the brain for TMS are not enough to determine if they are effective in priming the brain. The studies that include tDCS have small sample size and inconclusive results. The studies with tACS are using very high frequencies of 140 Hz to 250 Hz. The objective of this research study is to determine if priming the brain with tACS at 40 Hz or tRNS for 10 minutes is able to reduce the resting and active motor threshold. Therefore, for people with higher RMT and AMT, priming with tACS or tRNS could be used to lower intensities while stimulating the brain for treatments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
· Phase 2
· not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients
· NA
· not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes
· NA
· enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias
· NA
· recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
· Phase 2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 6 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05503823.